Asset
FERRIC PYROPHOSPHATE CITRATE
Rockwell Medical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04042324 | phase1_2 | completed | 2019-09-30 | 2020-01-16 | Rockwell Medical Technologies, Inc. | A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients |
| NCT03303144 | phase1_2 | completed | 2017-10-01 | 2017-12-28 | Rockwell Medical Technologies, Inc. | Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients |
| NCT04239391 | phase3 | unknown | 2020-09-01 | 2023-08-31 | Rockwell Medical Technologies, Inc. | Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC) |
| NCT02767128 | phase1 | completed | 2016-04-01 | 2016-04-01 | Rockwell Medical Technologies, Inc. | Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers |
| NCT02739100 | phase1 | completed | 2016-04-01 | 2016-07-01 | Rockwell Medical Technologies, Inc. | Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients |
FDA applications (3)
| Application | Type | Applicant |
|---|---|---|
| NDA 206317 | NDA | ROCKWELL MEDICAL INC |
| NDA 208551 | NDA | ROCKWELL MEDICAL INC |
| NDA 212860 | NDA | ROCKWELL MEDICAL INC |
Marketed products (4)
- TRIFERIC
- TRIFERIC
- TRIFERIC
- TRIFERIC AVNU